Corvus Pharmaceuticals (NASDAQ:CRVS) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) in a report released on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $11.00 price objective on the stock. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q4 2024 earnings at ($0.12) EPS and FY2029 earnings at $0.49 EPS.

Several other research analysts have also weighed in on the stock. StockNews.com lowered shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Oppenheimer lifted their price target on shares of Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. LADENBURG THALM/SH SH upped their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Finally, Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $12.38.

Corvus Pharmaceuticals Trading Up 7.4 %

Shares of CRVS opened at $5.83 on Thursday. The stock has a market cap of $374.62 million, a P/E ratio of -6.27 and a beta of 1.07. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The stock’s 50-day moving average price is $7.67 and its two-hundred day moving average price is $5.29.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Samlyn Capital LLC grew its holdings in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after buying an additional 3,774,658 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Corvus Pharmaceuticals during the 2nd quarter worth approximately $10,855,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Corvus Pharmaceuticals by 64.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after acquiring an additional 53,809 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Corvus Pharmaceuticals in the third quarter valued at approximately $74,000. Finally, State Street Corp lifted its position in shares of Corvus Pharmaceuticals by 48.2% in the third quarter. State Street Corp now owns 178,246 shares of the company’s stock worth $941,000 after purchasing an additional 57,943 shares in the last quarter. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.